Louvain-la-Neuve: A Belgian temple for success in cell therapy

15/09/2015 - 2 minutes

Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist.

novadip-innovative-cell-therapies-trans-logo1The financing round, led by New Science Ventures, will boost Novadip’s lead compound Creost, a natural ready-to-use 3D bone replacement derived from adipose stem cells. These mesenchymal stem cells are obtained after isolation from a minimally invasive subcutaneous procedure. Their osteogenic structure reconstructs critical size bone defects without the use of any scaffolding, a similar concept to Biom’Up’s MatriBone.

Novadip’s technology originates from research lead by Prof Denis Dufrane and colleagues at St Luc University Hospital and the Université Catholique de Louvain. The company’s recent success also illustrates the University’s ability to spin-off a technology that will have a significant impact on patients.

Novadip, however, is not the only cell therapist in town.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: